<DOC>
	<DOCNO>NCT02165904</DOCNO>
	<brief_summary>The study go 24 month , recruiting , treatment follow period patient . The first day patient first cellular administration . 3 dos administrate every 3 month first dose . When clinical trial finish , do complete check obtain parameter .</brief_summary>
	<brief_title>Subarachnoid Administration Adult Autologous Bone Marrow Mesenchymal Cells Expanded Incomplete ( SCI )</brief_title>
	<detailed_description>It clinical trial phase I , single center , non-randomized , uncontrolled , open prospective follow-up cohort patient chronic spinal cord injury ( SCI ) .10 patient include injury . Primary objective : Analyze possible clinical efficacy administration main adult mesenchymal autologous cell expand `` vitro '' patient incomplete chronically establish SCI . Secondary objective : Confirm safety treatment , study possible change cerebrospinal fluid ( CSF ) level ( Brain-derived neurotrophic factor ( BDNF ) , glial cell line-derived neurotrophic factor ( GDNF ) , nerve growth factor ( NGF ) , ciliary neurotrophic factor ( CNTF ) , Nerve Growth Factor 3 4 ( NT3 NT4 ) subarachnoid administration BMMC .</detailed_description>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<criteria>1 . Incomplete SCI 2 . Neurological deficit clinically stable least 12 month prior treatment , minimum oneyear evolution SCI . 3 . Neurophysiological confirmation incomplete SCI . 4 . The MRI study morphologically evaluate SCI . 5 . Age 18 70 year 6 . Thread Men woman compromise use anticonceptive issue first cell´s extraction 6 month last cell´s administration . 7 . Ability attend clinical followup perform physical therapy treatment period . 8 . Written sign informed consent , accord local regulation . 9 . Hematologic creatinin parameter , SGOT SGPT , within normal range , accord laboratory standard consider small variation could accept base clinical study team criterion . 1 . A classification ASIA FRANKEL clinical scale evaluate SCI . 2 . Neurophysiological record confirm complete SCI . 3 . Age 18 year 70 . 4 . Pregnancy lactation . 5 . Malignancy disease diagnose treat within last 5 year . 6 . Patients systemic disease represent additional risk treatment . 7 . Patients uncertain commitment follow physical therapy clinical visit well patient negative input previous phycological assessment . 8 . Inability assess SCI feature MRI either noise due spinal stabilization system cause . 9 . Patients currently hematopoietic growth factor treatment require maintain anticoagulation . 10 . Neurodegenerative disease additional . 11 . History substance abuse , psychiatric disease allergy protein product use process cell expansion . 12 . Positive serology HIV syphilis . 13 . Active Hepatitis B Hepatitis C. 14 . With reason would consider patient ineligible cell therapy accord investigator judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Analyze clinical efficacy subarachnoid administration</keyword>
	<keyword>autologous BMSC expand `` vitro ''</keyword>
</DOC>